Company / Revenue per Share
Neurocrine Biosciences Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$28.78
FY2025
5-year range
$11.02 / $28.78
FY2021-FY2025
Trend
+20.6%
vs FY2024
Sector context
#15 of 154
Health Care
What the data says
Among 154 Health Care companies, Neurocrine Biosciences is in the top 10% for revenue per share. Revenue per Share has increased for 3 consecutive years, from $11.02 in FY2022 to $28.78 in FY2025.
Based on SEC 10-K filings.
28.78 in FY2025 with a 5-year CAGR of +20.5%. Top quartile in the Health Care sector.
Improved from $19.56 to $28.78 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +37.7%
- 5-Year CAGR
- +20.5%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 154This company $28.78 Sector average $10.35
▼
+178.0% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's revenue per share has grown for 3 consecutive years.
- In FY2025, revenue per share increased 20.6% year-over-year.
- Ranks #15 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.78 | +20.6% |
| FY2024 | $23.86 | +22.0% |
| FY2023 | $19.56 | +77.4% |
| FY2022 | $11.02 | -9.1% |
| FY2021 | $12.12 | +7.0% |
| FY2020 | $11.33 | +30.6% |
| FY2019 | $8.68 | +70.8% |
| FY2018 | $5.08 | - |
| FY2017 | $0.00 | -100.0% |
| FY2016 | $0.17 | -32.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026